Ajanta Pharmaceuticals Q3 FY24 Results Live : profit rise by 56.14% YOY
Ajanta Pharmaceuticals Q3 FY24 Results Live : Revenue increased by 13.73% YoY & profit increased by 56.14% YoY02-02-2024
02-02-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Reg 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith copies of financial results of the Company for the quarter and nine months ended 31st December 2023 published in the newspapers on 1st February 2024.01-02-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2024 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EarningsAudio-Q3FY2024.mp331-01-2024
AJANTA PHARMA LTD. - 532331 - Cancellation Of Employee Stock Option (Esops)
Please note that the Nomination and Remuneration Committee of the Board of Directors in its meeting held today i.e on 31st January 2024 considered and approved cancellation of an aggregate of 3.750 stock options granted under the Companies ''Share Based Incentive Plan 2019 (SBIP)'' and the said options have been credited back to the ESOP pool.31-01-2024
AJANTA PHARMA LTD. - 532331 - Fixation Of Record Date For 2Nd Interim Dividend
The Board in its Meeting held today fixed Thursday, 8th February 2024 as the Record Date for the purpose of 2nd Interim Dividend.31-01-2024
AJANTA PHARMA LTD. - 532331 - Corporate Action-Board approves Dividend
The Board in its meeting held today has approved 2nd Interim Dividend. For more details please find enclosed herewith outcome of the Board Meeting.31-01-2024
AJANTA PHARMA LTD. - 532331 - Results For The Quarter And Nine Months Ended 31St December 2023
Results for Dec 202331-01-2024
AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
At the Board meeting held today, the Board has inter-alia approved and took on record Unaudited Financial results for the quarter and nine months ended 31st December 2023, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.31-01-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Further to our letter dated 23rd January 2024, kindly take note that the timing of post Board meeting Earning Conference Call scheduled on 31st January 2024 at 04:30 PM has been revised to 05:00 PM on the same day. We are enclosing herewith the revised schedule of Earnings Conference Call to be held on 31st January 2024, post Board meeting.25-01-2024
AJANTA PHARMA LTD. - 532331 - Correction Of Error In The Intimation Of Record Date
Vide our letters of even date, we have informed that at the Board Meeting scheduled on Wednesday, 31st January 2024, the Board of Directors will also consider declaration of 2nd interim dividend for the FY 2024 and fixation of Record Date for this purpose. In these intimations, the Record Date is inadvertently stated as Thursday, 8th December 2024 instead of 8th February 2024. In view thereof, please read the Record Date as Thursday, 8th February 2024 for the purpose of payment of 2nd interim dividend.25-01-2024